Tag
Anticoagulation therapy in adults aged 80 and older with atrial fibrillation is linked to reduced all-cause mortality despite an increased risk of gastrointestinal bleeding, supporting its continued use in selected elderly patients.
A landmark randomized trial demonstrates that atorvastatin reduces major cardiovascular events in adults aged 70 and older without established cardiovascular disease but does not extend disability-free survival, highlighting nuanced conside
Immunotherapy use in older patients with advanced endometrial cancer has increased over recent years but remains lower among the oldest and racial minorities, highlighting persisting treatment disparities.
This review synthesizes emerging evidence demonstrating robust effectiveness of RSV vaccination in reducing hospitalization, death, and severe outcomes among elderly nursing home residents during the vaccine’s inaugural season.
Cushing’s syndrome in older adults requires a tailored diagnostic approach and individualized management that prioritizes functional status and quality of life over chronological age, accounting for atypical presentations and comorbidities.
In frail elderly Asian AF patients stable on warfarin, transitioning to DOACs increased risks of bleeding, thromboembolic events, and mortality, emphasizing cautious individualized management.
A 2025 Cochrane review of 24 non-randomised studies (26,127 participants) found very low‑certainty evidence comparing conservative kidney management (CKM) with dialysis in people aged ≥65 with stage 5 chronic kidney disease; survival and qu
Danish registry data (1999–2022) show large reductions in stroke across age groups with widespread oral anticoagulant (OAC) uptake, but only modest stroke gains and rising intracerebral hemorrhage in patients ≥85 years, highlighting the nee
ASPREE randomized ~19,000 older adults to low‑dose aspirin or placebo. Over ~4.7 years, aspirin did not improve disability‑free survival or reduce cardiovascular events, increased major bleeding, and showed a surprising rise in cancer‑relat
In a multi-center cohort of 345 surgically treated patients aged 70 or older with tonsil or base‑of‑tongue SCC, p16 positivity was associated with substantially better 5‑year overall and disease‑free survival compared with p16‑negative tumo
This study demonstrates that statin therapy effectively reduces cardiovascular risk and all-cause mortality in older adults with chronic kidney disease and hypercholesterolemia, without increasing major adverse events, even in very elderly
This study compares long-acting injectable to oral antipsychotics in older schizophrenia patients, highlighting benefits in relapse prevention and mortality reduction, with specific considerations for adverse effects.
Extended follow-up from the ASPREE-XT study shows low-dose aspirin does not improve healthy lifespan—defined as survival free of dementia, persistent disability, or death—in healthy older adults, and its risks include increased major hemorr
The DAN-RSV trial demonstrates that RSV vaccination significantly lowers all-cause cardiorespiratory hospitalizations among older adults, suggesting vaccines may reduce infection-triggered cardiovascular complications and benefit chronic di
The RETREAT-FRAIL trial found no survival benefit from progressively reducing antihypertensive medications in frail nursing home residents aged ≥80 with controlled blood pressure, supporting individualized treatment strategies.
The ASTER 70s trial found that adding chemotherapy to hormonotherapy did not improve survival but increased toxicity in women aged 70+ with high-risk ER+/HER2- breast cancer.
A large US study finds adjuvanted and high-dose quadrivalent influenza vaccines provide comparable protection against lab-confirmed flu in seniors, supporting current immunization guidelines.
Significant variation exists in bone health management for older women receiving endocrine therapy for breast cancer, highlighting the need for standardized care.
A large-scale emulated trial found no clear overall reduction in dementia risk with GLP-1 receptor agonists versus DPP-4 inhibitors in older adults with type 2 diabetes, though age-specific effects warrant further investigation.
